At the news
? MIXEDIMPACT 6/10 PRESS-RELEASE filed Jun 16, 2026 at 19:43 ET
Nano Dimension issued a shareholder update defending its proposed business combination with Infinite Epigenetics, an AI-powered diagnostics company, responding to activist Murchinson's criticism. The transaction would value Nano at net cash plus a 20% premium, but definitive terms are not yet finalized and the deal faces shareholder opposition.
- Nano Dimension proposes a business combination with Infinite Epigenetics, transitioning from 3D printing to AI-powered preventive health and diagnostics.
- The transaction would value Nano at net cash plus a 20% premium, with shareholders receiving equity in the combined entity.
- Infinite Epigenetics operates a CLIA-certified lab, has processed over 120,000 biological samples, published over 50 peer-reviewed studies, and has a network of over 7,500 healthcare providers.
- Activist investor Murchinson has requisitioned an extraordinary shareholder meeting to replace a majority of Nano's Board, opposing the deal.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access